NRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic Pain

IND builds on previously-published, preliminary evidence of efficacy Filing is supported by robust manufacturing, pre-clinical and clinical data already reviewed by FDA for NRX-101 associated with treatment of bipolar depression RADNOR, Pa., Aug. 30, 2023 /PRNewswire/ – NRx…